{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:56:09Z","timestamp":1792068969916,"version":"4.4.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s00125-025-06453-z","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T10:04:53Z","timestamp":1749117893000},"page":"1924-1936","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Glucagon-like peptide-1 receptor agonists and gastrointestinal cancer risk in individuals with type 2 diabetes"],"prefix":"10.1007","volume":"68","author":[{"given":"Chia-Chih","family":"Kuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Hsiang","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Hsien","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Wen","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Yu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsing-Tao","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Cheng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"key":"6453_CR1","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41574-024-00979-9","volume":"20","author":"S Ansari","year":"2024","unstructured":"Ansari S, Khoo B, Tan T (2024) Targeting the incretin system in obesity and type 2 diabetes mellitus. Nat Rev Endocrinol 20:447\u2013459. https:\/\/doi.org\/10.1038\/s41574-024-00979-9","journal-title":"Nat Rev Endocrinol"},{"key":"6453_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-024-0752-9","author":"CC Kuo","year":"2024","unstructured":"Kuo CC, Chuang MH, Li CH et al (2024) Semaglutide and the risk of adverse liver outcomes in patients with nonalcoholic fatty liver disease and type 2 diabetes: a multi-institutional cohort study. Hepatol Int. https:\/\/doi.org\/10.1007\/s12072-024-0752-9","journal-title":"Hepatol Int"},{"issue":"7","key":"6453_CR3","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1111\/apt.18502","volume":"61","author":"CC Kuo","year":"2025","unstructured":"Kuo CC, Chuang MH, Li CH et al (2025) Glucagon-like peptide-1 receptor agonists and liver outcomes in patients with MASLD and type 2 diabetes. Aliment Pharmacol Ther 61(7):1163\u20131174. https:\/\/doi.org\/10.1111\/apt.18502","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"6453_CR4","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1111\/apt.70007","volume":"61","author":"CC Kuo","year":"2025","unstructured":"Kuo CC, Li CH, Chuang MH et al (2025) Impact of GLP-1 receptor agonists on alcohol-related liver disease development and progression in alcohol use disorder. Aliment Pharmacol Ther 61(8):1343\u20131356. https:\/\/doi.org\/10.1111\/apt.70007","journal-title":"Aliment Pharmacol Ther"},{"key":"6453_CR5","doi-asserted-by":"publisher","first-page":"e13823","DOI":"10.1111\/obr.13823","volume":"25","author":"MS Kim","year":"2024","unstructured":"Kim MS, Lee I, Natarajan P et al (2024) Integration of observational and causal evidence for the association between adiposity and 17 gastrointestinal outcomes: an umbrella review and meta-analysis. Obes Rev 25:e13823. https:\/\/doi.org\/10.1111\/obr.13823","journal-title":"Obes Rev"},{"key":"6453_CR6","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1056\/NEJMsr1606602","volume":"375","author":"B Lauby-Secretan","year":"2016","unstructured":"Lauby-Secretan B, Scoccianti C, Loomis D et al (2016) Body fatness and cancer \u2013 viewpoint of the IARC Working Group. N Engl J Med 375:794\u2013798. https:\/\/doi.org\/10.1056\/NEJMsr1606602","journal-title":"N Engl J Med"},{"key":"6453_CR7","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1001\/jama.2023.19574","volume":"330","author":"M Sodhi","year":"2023","unstructured":"Sodhi M, Rezaeianzadeh R, Kezouh A et al (2023) Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA 330:1795\u20131797. https:\/\/doi.org\/10.1001\/jama.2023.19574","journal-title":"JAMA"},{"key":"6453_CR8","doi-asserted-by":"publisher","first-page":"S245","DOI":"10.2337\/dcS13-2004","volume":"36","author":"MA Nauck","year":"2013","unstructured":"Nauck MA, Friedrich N (2013) Do GLP-1\u2013based therapies increase cancer risk? Diabetes Care 36:S245\u2013S252. https:\/\/doi.org\/10.2337\/dcS13-2004","journal-title":"Diabetes Care"},{"key":"6453_CR9","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1517\/14740338.2015.987122","volume":"14","author":"A Consoli","year":"2015","unstructured":"Consoli A, Formoso G (2015) Potential side effects to GLP-1 agonists: understanding their safety and tolerability. Expert Opin Drug Saf 14:207\u2013218. https:\/\/doi.org\/10.1517\/14740338.2015.987122","journal-title":"Expert Opin Drug Saf"},{"key":"6453_CR10","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.2337\/dc12-2713","volume":"36","author":"PC Butler","year":"2013","unstructured":"Butler PC, Elashoff M, Elashoff R et al (2013) A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 36:2118\u20132125. https:\/\/doi.org\/10.2337\/dc12-2713","journal-title":"Diabetes Care"},{"key":"6453_CR11","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.2337\/db12-1686","volume":"62","author":"AE Butler","year":"2013","unstructured":"Butler AE, Campbell-Thompson M, Gurlo T et al (2013) Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 62:2595\u20132604. https:\/\/doi.org\/10.2337\/db12-1686","journal-title":"Diabetes"},{"key":"6453_CR12","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1053\/j.gastro.2011.02.018","volume":"141","author":"M Elashoff","year":"2011","unstructured":"Elashoff M, Matveyenko AV, Gier B et al (2011) Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 141:150\u2013156. https:\/\/doi.org\/10.1053\/j.gastro.2011.02.018","journal-title":"Gastroenterology"},{"key":"6453_CR13","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.cmet.2015.02.005","volume":"21","author":"JA Koehler","year":"2015","unstructured":"Koehler JA, Baggio LL, Yusta B et al (2015) GLP-1R agonists promote normal and neoplastic intestinal growth through mechanisms requiring Fgf7. Cell Metab 21:379\u2013391. https:\/\/doi.org\/10.1016\/j.cmet.2015.02.005","journal-title":"Cell Metab"},{"key":"6453_CR14","doi-asserted-by":"publisher","first-page":"107401","DOI":"10.1016\/j.phrs.2024.107401","volume":"208","author":"G Figlioli","year":"2024","unstructured":"Figlioli G, Piovani D, Peppas S et al (2024) Glucagon-like peptide-1 receptor agonists and risk of gastrointestinal cancers: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res 208:107401","journal-title":"Pharmacol Res"},{"key":"6453_CR15","doi-asserted-by":"publisher","first-page":"1534365","DOI":"10.1155\/2019\/1534365","volume":"2019","author":"Y Liu","year":"2019","unstructured":"Liu Y, Zhang X, Chai S et al (2019) Risk of malignant neoplasia with glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes: a meta-analysis. J Diabetes Res 2019:1534365","journal-title":"J Diabetes Res"},{"key":"6453_CR16","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s12020-019-02055-z","volume":"66","author":"C Cao","year":"2019","unstructured":"Cao C, Yang S, Zhou Z (2019) GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials. Endocrine 66:157\u2013165. https:\/\/doi.org\/10.1007\/s12020-019-02055-z","journal-title":"Endocrine"},{"key":"6453_CR17","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1097\/MPA.0000000000002197","volume":"51","author":"A Krishnan","year":"2022","unstructured":"Krishnan A, Hadi Y, Hutson WR et al (2022) Glucagon-like peptide 1-based therapies and risk of pancreatic cancer in patients with diabetes and obesity. Pancreas 51:1398\u20131403. https:\/\/doi.org\/10.1097\/MPA.0000000000002197","journal-title":"Pancreas"},{"key":"6453_CR18","doi-asserted-by":"publisher","first-page":"e2421305","DOI":"10.1001\/jamanetworkopen.2024.21305","volume":"7","author":"L Wang","year":"2024","unstructured":"Wang L, Xu R, Kaelber DC et al (2024) Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes. JAMA Netw Open 7:e2421305","journal-title":"JAMA Netw Open"},{"key":"6453_CR19","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1001\/jamaoncol.2023.5573","volume":"10","author":"L Wang","year":"2024","unstructured":"Wang L, Wang W, Kaelber DC et al (2024) GLP-1 receptor agonists and colorectal cancer risk in drug-naive patients with type 2 diabetes, with and without overweight\/obesity. JAMA Oncol 10:256\u2013258. https:\/\/doi.org\/10.1001\/jamaoncol.2023.5573","journal-title":"JAMA Oncol"},{"key":"6453_CR20","doi-asserted-by":"publisher","first-page":"ooad035","DOI":"10.1093\/jamiaopen\/ooad035","volume":"6","author":"MB Palchuk","year":"2023","unstructured":"Palchuk MB, London JW, Perez-Rey D et al (2023) A global federated real-world data and analytics platform for research. JAMIA Open 6:ooad035. https:\/\/doi.org\/10.1093\/jamiaopen\/ooad035","journal-title":"JAMIA Open"},{"issue":"3","key":"6453_CR21","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1093\/jnci\/djae260","volume":"117","author":"L Wang","year":"2025","unstructured":"Wang L, Wang Q, Li L et al (2025) GLP-1 receptor agonists and pancreatic cancer risk: target trial emulation using real-world data. J Natl Cancer Inst 117(3):476\u2013485. https:\/\/doi.org\/10.1093\/jnci\/djae260","journal-title":"J Natl Cancer Inst"},{"key":"6453_CR22","first-page":"100370","volume":"38","author":"A Krishnan","year":"2024","unstructured":"Krishnan A, Schneider CV, Arkenau HT et al (2024) Association between incretin-based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: a large population-based matched cohort study. J Clin Transl Endocrinol 38:100370","journal-title":"J Clin Transl Endocrinol"},{"key":"6453_CR23","doi-asserted-by":"publisher","first-page":"e2350408","DOI":"10.1001\/jamanetworkopen.2023.50408","volume":"7","author":"R Dankner","year":"2024","unstructured":"Dankner R, Murad H, Agay N et al (2024) Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk in patients with type 2 diabetes. JAMA Netw Open 7:e2350408","journal-title":"JAMA Netw Open"},{"key":"6453_CR24","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.metabol.2018.11.001","volume":"92","author":"KI Avgerinos","year":"2019","unstructured":"Avgerinos KI, Spyrou N, Mantzoros CS et al (2019) Obesity and cancer risk: emerging biological mechanisms and perspectives. Metabolism 92:121\u2013135. https:\/\/doi.org\/10.1016\/j.metabol.2018.11.001","journal-title":"Metabolism"},{"key":"6453_CR25","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1016\/S2213-8587(18)30150-5","volume":"6","author":"J Pearson-Stuttard","year":"2018","unstructured":"Pearson-Stuttard J, Zhou B, Kontis V et al (2018) Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment. Lancet Diabetes Endocrinol 6:e6\u2013e15. https:\/\/doi.org\/10.1016\/S2213-8587(18)30150-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6453_CR26","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.1200\/JCO.2016.67.4283","volume":"34","author":"NM Iyengar","year":"2016","unstructured":"Iyengar NM, Gucalp A, Dannenberg AJ et al (2016) Obesity and cancer mechanisms: tumor microenvironment and inflammation. J Clin Oncol 34:4270\u20134276. https:\/\/doi.org\/10.1200\/JCO.2016.67.4283","journal-title":"J Clin Oncol"},{"key":"6453_CR27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/nrm.2017.89","volume":"19","author":"RA Haeusler","year":"2018","unstructured":"Haeusler RA, McGraw TE, Accili D (2018) Biochemical and cellular properties of insulin receptor signalling. Nat Rev Mol Cell Biol 19:31\u201344. https:\/\/doi.org\/10.1038\/nrm.2017.89","journal-title":"Nat Rev Mol Cell Biol"},{"key":"6453_CR28","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.tem.2010.06.007","volume":"21","author":"EJ Gallagher","year":"2010","unstructured":"Gallagher EJ, LeRoith D (2010) The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab 21:610\u2013618. https:\/\/doi.org\/10.1016\/j.tem.2010.06.007","journal-title":"Trends Endocrinol Metab"},{"key":"6453_CR29","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/nrc3215","volume":"12","author":"M Pollak","year":"2012","unstructured":"Pollak M (2012) The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 12:159\u2013169. https:\/\/doi.org\/10.1038\/nrc3215","journal-title":"Nat Rev Cancer"},{"key":"6453_CR30","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1074\/jbc.M209423200","volume":"278","author":"Y Li","year":"2003","unstructured":"Li Y, Hansotia T, Yusta B et al (2003) Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 278:471\u2013478. https:\/\/doi.org\/10.1074\/jbc.M209423200","journal-title":"J Biol Chem"},{"key":"6453_CR31","doi-asserted-by":"publisher","first-page":"E1431","DOI":"10.1152\/ajpendo.00017.2014","volume":"306","author":"H Zhao","year":"2014","unstructured":"Zhao H, Wei R, Wang L et al (2014) Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner. Am J Physiol Endocrinol Metab 306:E1431\u2013E1441. https:\/\/doi.org\/10.1152\/ajpendo.00017.2014","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"6453_CR32","doi-asserted-by":"publisher","first-page":"602574","DOI":"10.3389\/fcell.2020.602574","volume":"8","author":"Y Fang","year":"2020","unstructured":"Fang Y, Ji L, Zhu C et al (2020) Liraglutide alleviates hepatic steatosis by activating the TFEB-regulated autophagy-lysosomal pathway. Front Cell Dev Biol 8:602574","journal-title":"Front Cell Dev Biol"},{"key":"6453_CR33","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1136\/gutjnl-2023-329651","volume":"73","author":"BD Liu","year":"2024","unstructured":"Liu BD, Udemba SC, Liang K et al (2024) Shorter-acting glucagon-like peptide-1 receptor agonists are associated with increased development of gastro-oesophageal reflux disease and its complications in patients with type 2 diabetes mellitus: a population-level retrospective matched cohort study. Gut 73:246\u2013254. https:\/\/doi.org\/10.1136\/gutjnl-2023-329651","journal-title":"Gut"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-025-06453-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-025-06453-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-025-06453-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:02:20Z","timestamp":1780617740000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-025-06453-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["6453"],"URL":"https:\/\/doi.org\/10.1007\/s00125-025-06453-z","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,5]]},"assertion":[{"value":"27 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The data utilised in this study were obtained from the TriNetX Research Network, a global federated health research platform providing access to de-identified electronic medical records from participating healthcare organisations. Due to data use agreements and privacy regulations, the individual-level data are not publicly available. However, aggregated data supporting the findings of this study can be accessed through the TriNetX platform by qualified researchers upon reasonable request and subject to approval by TriNetX.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 relationships and activities"}},{"value":"C-CK and C-CL conceived and designed the study. C-CK and C-CL performed the statistical analysis, prepared the first draft of the manuscript, and revised the draft. All authors contributed to the interpretation of data and critically revised the content of the draft. C-CK and H-TK supervised the study. All authors gave final approval of the version to be published. As such, they had full access to all data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. C-CL is the guarantor of this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Contribution statement"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}